Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03873402 · ClinicalTrials.gov registry record · Phase 3

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

A Phase 3 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
437
Enrollment target
20
Study locations

NCT03873402 is a Phase 3 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 437 participants, above the 239-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03873402, a Phase 3 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
437 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Ipilimumab
  • OTHER Ipilimumab placebo

Study Locations (20)

Other

  • Local Institution - 0005 - Córdoba
  • Local Institution - 0002 - San Juan
  • Local Institution - 0033 - Graz
  • Local Institution - 0031 - Vienna
  • Local Institution - 0032 - Wels

Massachusetts

  • Local Institution - 0066 - Boston
  • Local Institution - 0088 - Boston
  • Local Institution - 0086 - Boston

Buenos Aires

  • Local Institution - 0100 - Capital Federal
  • Local Institution - 0011 - Ciudad Autónoma de Buenos Aires
  • Local Institution - 0060 - Mar del Plata

Región de Valparaíso

  • Local Institution - 0004 - Viña del Mar
  • Local Institution - 0012 - Viña El Mar

District of Columbia

  • Local Institution - 0013 - Washington D.C.

Georgia

  • Local Institution - 0053 - Athens

Pennsylvania

  • The Reading Hosp Med Ctr Reg Cancer Ctr - West Reading

South Carolina

  • Local Institution - 0084 - Charleston

Trial Details

FieldValue
Enrollment Target 437 participants
Start Date 2019-06-21
Est. Completion 2027-03-11
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03873402

The ClinicalTrials.gov registry entry for NCT03873402 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 437 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 239-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (83% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT03873402 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Massachusetts, Buenos Aires.

Frequently Asked Questions

What is clinical trial NCT03873402 about?

NCT03873402 is a clinical study titled "A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer". The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.

What is the current status of trial NCT03873402?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 437 participants. The study started on 2019-06-21. Estimated completion is 2027-03-11.

What conditions does trial NCT03873402 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT03873402?

The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Ipilimumab placebo (OTHER).

Who is sponsoring clinical trial NCT03873402?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03873402 being conducted?

This trial has 20 study locations across District of Columbia, Georgia, Massachusetts, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.